ArticleBrain and behavior2025
Assessing Causality Between Plasma Brain-Derived Neurotrophic Factor With Major Depression Disorder: A Bidirectional Mendelian Randomization Study.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis study employed a two-sample Mendelian randomization (MR) approach to investigate the bidirectional relationship between brain-derived neurotrophic factor (BDNF) and major depressive disorder (MDD), addressing gaps left by prior observational studies.
methodsWe utilized Genome-Wide Association Study (GWAS) datasets, including MDD information from the Psychiatric Genomics Consortium (PGC) and the UK Biobank (N = 500,199), along with plasma BDNF measurements from the FinnGen Consortium (N = 619). In a subsequent phase, we analyzed MDD data from FinnGen (N = 448,069) with plasma BDNF data from three additional GWAS sources: UK Biobank (N = 33,924), deCODE (N = 35,353), and INTERVAL (N = 3301). Multiple MR methods were applied to ensure a robust analysis.
resultsThe inverse variance weighted (IVW) method revealed no significant association between plasma BDNF levels and the risk of developing MDD (IVW odds ratio [OR] = 1.00, 95% confidence interval [CI] = 0.99-1.01, p = 0.769). Similarly, no causal effect of the BDNF gene on MDD was identified (OR = 0.91, CI = 0.23-3.56, p = 0.893). Furthermore, there was no evidence supporting a causal link between MDD and plasma BDNF levels (OR = 0.99, CI = 0.89-1.09, p = 0.783). The second phase of analysis confirmed the absence of bidirectional causal relationships.
conclusionThis bidirectional MR analysis provides no evidence of a causal association between plasma BDNF levels and MDD. These findings prompt a re-evaluation of plasma BDNF as a biomarker for MDD and emphasize the need for further investigation into its functional role within the plasma as well as its levels and activity in the brain and cerebrospinal fluid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.